SEC Form 4 · accession 0001683168-26-006592
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Bitterman
Officer — Chairman, Pres. & CEO · Director
Period of report
Aug 18, 2026
Accepted (ET)
Aug 19, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.0001 par valueF1 | Aug 18, 2026 | P | 10,000 | $1.06 | A | 431,421 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes shares of common stock underlying unvested restricted stock units.